Edition:
United States

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

15.27USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$15.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,918
52-wk High
$19.90
52-wk Low
$6.02

Latest Key Developments (Source: Significant Developments)

Aquinox Pharma announces year end 2016 financial results
Thursday, 9 Mar 2017 04:06pm EST 

Aquinox Pharmaceuticals Inc : Aquinox Pharmaceuticals announces year end 2016 financial results .Aquinox Pharmaceuticals Inc says net loss for year ended december 31, 2016 was $37.0 million compared to a net loss of $21.9 million for 2015.  Full Article

T. Rowe Price Associates Inc reports 14.4 pct passive stake in Aquinox Pharmaceuticals
Tuesday, 11 Oct 2016 10:10am EDT 

T. Rowe Price Associates Inc:T. Rowe Price Associates Inc reports 14.4 percent passive stake in Aquinox Pharmaceuticals Inc as of sept. 30 - SEC filing.  Full Article

Aquinox Pharmaceuticals Inc - qtrly loss per share $0.63
Thursday, 4 Aug 2016 04:15pm EDT 

Aquinox Pharmaceuticals Inc : Aquinox Pharmaceuticals announces second quarter 2016 financial results . Qtrly loss per share $0.63 .Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Aquinox Pharmaceuticals reports Q1 net loss per common stock of $0.39
Tuesday, 10 May 2016 09:05am EDT 

Aquinox Pharmaceuticals Inc : Aquinox pharmaceuticals inc qtrly net loss per common stock 0.39 . Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S .Aquinox pharmaceuticals announces first quarter 2016 financial results.  Full Article

Aquinox Pharmaceuticals Inc announces closing of $98.0 million public offering of common stock
Wednesday, 16 Sep 2015 09:15am EDT 

Aquinox Pharmaceuticals Inc:Announces closing of $98.0 million public offering of common stock, including full exercise of underwriters' option to purchase additional shares.Aquinox intends to use the net proceeds from this offering to fund clinical research and development of AQX-1125 in bladder pain syndrome/interstitial cystitis.Leerink Partners, Canaccord Genuity and Guggenheim Securities acted as joint book-running managers for the offering.Needham & Company acted as lead manager.  Full Article

Aquinox Prices Public Offering of Common Stock
Wednesday, 9 Sep 2015 10:11pm EDT 

Aquinox Pharmaceuticals Inc:Says announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $15.50 per share.In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price.The offering is expected to close on September 15, 2015, subject to customary closing conditions.  Full Article

Aquinox Pharmaceuticals, Inc announces proposed public offering of common stock
Tuesday, 8 Sep 2015 04:01pm EDT 

Aquinox Pharmaceuticals, Inc:Announces proposed public offering of common stock.Says intends to offer and sell, $75 million of its common stock in an underwritten public offering.  Full Article

Aquinox Pharmaceuticals Inc results from FLAGSHIP Trial With AQX-1125
Thursday, 9 Jul 2015 08:30am EDT 

Aquinox Pharmaceuticals Inc:Announces results from flagship trial with aqx-1125 in chronic obstructive pulmonary disease patients with frequent exacerbations.Atients treated with 200 mg oral once daily aqx-1125 for 12 wks demonstrated no difference in copd symptoms.On secondary endpoint of medically treated exacerbations there was also no benefit observed with aqx-1125.Says overall adverse event rate was similar between aqx-1125 and placebo.Says consistent with past results, the flagship trial demonstrated aqx-1125 to be well tolerated.Its phase 2 flagship clinical trial failed to demonstrate efficacy in copd patients with history of frequent exacerbations.  Full Article

Aquinox Pharmaceuticals, Inc announces results from bladder pain syndrome/interstitial cystitis
Thursday, 25 Jun 2015 08:30am EDT 

Aquinox Pharmaceuticals, Inc:Announces results from leadership trial with aqx-1125 in patients with bladder pain syndrome/interstitial cystitis.Says "it did not meet the trial statistical endpoint".Says secondary endpoints are currently being analyzed and will be reported at a future meeting.  Full Article

More From Around the Web